Page last updated: 2024-12-11

bay 12-9566

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Bay 12-9566: an angiogenesis inhibitor with matrix metalloproteinase inhibitory activity [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6918336
CHEMBL ID261932
CHEBI ID188765
SCHEMBL ID153066
MeSH IDM0292626

Synonyms (39)

Synonym
tanomastat
bay-12-9566
tanomastat (usan/inn)
D03802
179545-77-8
bdbm50084661
4-(4''-chloro-biphenyl-4-yl)-4-oxo-2-phenylsulfanylmethyl-butyric acid(bay-12-9566)
bay 12-9566
bay-129566
CHEMBL261932 ,
(2s)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulanylmethyl)butanoic acid
CHEBI:188765
am1zx94exh ,
(1,1'-biphenyl)-4-butanoic acid, 4'-chloro-gamma-oxo-alpha-((phenylthio)methyl)-, (s)-
unii-am1zx94exh
(s)-4'-chloro-gamma-oxo-alpha-((phenylthio)methyl)(1,1'-biphenyl)-4-butanoic acid
tanomastat [usan:inn]
bay 12-9566n
bay 129566
(s)-3-((4'-chloro-4-biphenylyl)carbonyl)-2-((phenylthio)methyl)propionic acid
(2s)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid
(1,1'-biphenyl)-4-butanoic acid, 4'-chloro-gamma-oxo-alpha-((phenylthio)methyl)-, (alphas)-
AKOS015911399
tanomastat [who-dd]
tanomastat [usan]
tanomastat [inn]
gtpl6468
SCHEMBL153066
(s)-4-(4'-chloro-[1,1'-biphenyl]-4-yl)-4-oxo-2-((phenylthio)methyl)butanoic acid
bay12-9566
(s)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid
HY-12168
CS-0003131
DB06276
EX-A7633
C90420
(s)-4-(4'-chloro-[1,1'-biphenyl]-4-yl)-4-oxo-2-((phenylthio)methyl)butanoicacid
DTXSID60870145
[1,1'-biphenyl]-4-butanoic acid, 4'-chloro-gamma-oxo-alpha-[(phenylthio)methyl]-, (alphas)-

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" BAY 12-9566 was well tolerated in all treatment groups, and no serious adverse events occurred during the study."( Effect of age and gender on the safety, tolerability, and pharmacokinetics of BAY 12-9566 in healthy subjects.
Lathia, C; Shah, A; Sundaresan, P, 2001
)
1.45

Pharmacokinetics

AY 12-9566 and 5-fluorouracil were investigated in osteoarthritis (OA) patients. There was no interaction between the two drugs. No effects were seen on the BAY 12/9566 pharmacokinetic values.

ExcerptReferenceRelevance
"The pharmacokinetic interactions between BAY 12-9566 and two nonsteroidal anti-inflammatory drugs (NSAIDs), naproxen and ibuprofen, were investigated in osteoarthritis (OA) patients."( Pharmacokinetics, safety, and tolerability of BAY 12-9566 and nonsteroidal anti-inflammatory agents (naproxen, ibuprofen) during coadministration in patients with osteoarthritis.
Agarwal, V; Liu, P; Shah, A; Sundaresan, P; Woodruff, M, 2001
)
0.83
" Peak plasma concentration, time to reach peak plasma concentration, the area under the concentration-time curve, oral clearance, volume of distribution, and elimination half-life were calculated."( Effect of age and gender on the safety, tolerability, and pharmacokinetics of BAY 12-9566 in healthy subjects.
Lathia, C; Shah, A; Sundaresan, P, 2001
)
0.54
" Pharmacokinetic analyses for both BAY 12-9566 and 5-fluorouracil were performed."( An NCIC CTG phase I/pharmacokinetic study of the matrix metalloproteinase and angiogenesis inhibitor BAY 12-9566 in combination with 5-fluorouracil/leucovorin.
Agarwal, V; Chouinard, E; Goel, R; Hirte, H; Huan, S; Humphrey, R; Lathia, C; Matthews, S; Roach, J; Seymour, L; Stafford, S; Stewart, DJ; Walsh, W; Waterfield, B, 2005
)
0.82
" Pharmacokinetic analysis suggested there was no interaction between BAY 12-9566 and 5-fluorouracil."( An NCIC CTG phase I/pharmacokinetic study of the matrix metalloproteinase and angiogenesis inhibitor BAY 12-9566 in combination with 5-fluorouracil/leucovorin.
Agarwal, V; Chouinard, E; Goel, R; Hirte, H; Huan, S; Humphrey, R; Lathia, C; Matthews, S; Roach, J; Seymour, L; Stafford, S; Stewart, DJ; Walsh, W; Waterfield, B, 2005
)
0.78
" Although there is some evidence of a clinical interaction, there is no apparent pharmacokinetic interaction."( An NCIC CTG phase I/pharmacokinetic study of the matrix metalloproteinase and angiogenesis inhibitor BAY 12-9566 in combination with 5-fluorouracil/leucovorin.
Agarwal, V; Chouinard, E; Goel, R; Hirte, H; Huan, S; Humphrey, R; Lathia, C; Matthews, S; Roach, J; Seymour, L; Stafford, S; Stewart, DJ; Walsh, W; Waterfield, B, 2005
)
0.54
" No effects were seen on the BAY 12-9566 pharmacokinetic values."( An NCIC-CTG phase I dose escalation pharmacokinetic study of the matrix metalloproteinase inhibitor BAY 12-9566 in combination with doxorubicin.
Agarwal, V; Chouinard, E; Goel, R; Hirte, H; Huan, S; Humphrey, R; Lathia, C; Matthews, S; Schwartz, B; Seymour, AL; Stafford, S; Stewart, D; Waterfield, B, 2005
)
0.84
" Plasma concentrations of BAY and VP-16 were measured to investigate pharmacokinetic interactions."( A phase I and pharmacokinetic study of the selective, non-peptidic inhibitor of matrix metalloproteinase BAY 12-9566 in combination with etoposide and carboplatin.
Alberts, SR; Erlichman, C; Furth, A; Lathia, CD; Molina, JR; Reid, JM; Safgren, SL; Sloan, JA, 2005
)
0.54

Compound-Compound Interactions

AY 12-9566 can be safely administered with full doses of doxorubicin without evidence of clinical interaction. This phase I study was performed to evaluate the safety, tolerability, and efficacy of the oral matrix metalloproteinase inhibitors.

ExcerptReferenceRelevance
"This phase I study was performed to evaluate the safety, tolerability, and efficacy of the oral matrix metalloproteinase inhibitor BAY 12-9566 in combination with 5-fluorouracil/leucovorin in patients with advanced solid tumours, and to identify the maximum tolerated dose and the dose for use in future studies."( An NCIC CTG phase I/pharmacokinetic study of the matrix metalloproteinase and angiogenesis inhibitor BAY 12-9566 in combination with 5-fluorouracil/leucovorin.
Agarwal, V; Chouinard, E; Goel, R; Hirte, H; Huan, S; Humphrey, R; Lathia, C; Matthews, S; Roach, J; Seymour, L; Stafford, S; Stewart, DJ; Walsh, W; Waterfield, B, 2005
)
0.75
" was given with 350 mg/m2 5-fluorouracil/20 mg/m2 leucovorin x 5 days q28 days."( An NCIC CTG phase I/pharmacokinetic study of the matrix metalloproteinase and angiogenesis inhibitor BAY 12-9566 in combination with 5-fluorouracil/leucovorin.
Agarwal, V; Chouinard, E; Goel, R; Hirte, H; Huan, S; Humphrey, R; Lathia, C; Matthews, S; Roach, J; Seymour, L; Stafford, S; Stewart, DJ; Walsh, W; Waterfield, B, 2005
)
0.54
"This phase I study was performed to evaluate the safety, tolerability, and efficacy of the oral matrix metalloproteinase inhibitor BAY 12-9566 in combination with doxorubicin in patients with advanced solid tumours, and to identify the maximum tolerated dose of these agents in combination and the dose for use in subsequent studies."( An NCIC-CTG phase I dose escalation pharmacokinetic study of the matrix metalloproteinase inhibitor BAY 12-9566 in combination with doxorubicin.
Agarwal, V; Chouinard, E; Goel, R; Hirte, H; Huan, S; Humphrey, R; Lathia, C; Matthews, S; Schwartz, B; Seymour, AL; Stafford, S; Stewart, D; Waterfield, B, 2005
)
0.75
"BAY 12-9566 can be safely administered with full doses of doxorubicin without evidence of clinical interaction."( An NCIC-CTG phase I dose escalation pharmacokinetic study of the matrix metalloproteinase inhibitor BAY 12-9566 in combination with doxorubicin.
Agarwal, V; Chouinard, E; Goel, R; Hirte, H; Huan, S; Humphrey, R; Lathia, C; Matthews, S; Schwartz, B; Seymour, AL; Stafford, S; Stewart, D; Waterfield, B, 2005
)
1.99
" This phase I study of oral BAY was conducted to evaluate the safety and pharmacokinetics of BAY when administered in combination with etoposide (VP-16) or in combination with VP-16 and carboplatin (CBDCA) in subjects with advanced cancer."( A phase I and pharmacokinetic study of the selective, non-peptidic inhibitor of matrix metalloproteinase BAY 12-9566 in combination with etoposide and carboplatin.
Alberts, SR; Erlichman, C; Furth, A; Lathia, CD; Molina, JR; Reid, JM; Safgren, SL; Sloan, JA, 2005
)
0.54

Bioavailability

ExcerptReferenceRelevance
" The hydroxamate peptidomimetic inhibitor batimastat and its orally bioavailable analogue marimastat, which bind covalently to the zinc atom at the MMP-active site, were the first MMP inhibitors to be studied in detail."( Development of matrix metalloproteinase inhibitors in cancer therapy.
Eckhardt, SG; Hidalgo, M, 2001
)
0.31
" Optimization of the substituent adjacent to the retrohydroxamate center in this series led to the clinical candidate ABT-518 (6), a highly potent, selective, orally bioavailable MMP inhibitor that has been shown to significantly inhibit tumor growth in animal cancer models."( Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.
Albert, DH; Bouska, JJ; Curtin, ML; Dai, Y; Davidsen, SK; Elmore, IN; Florjancic, AS; Garland, RB; Goodfellow, CL; Guo, Y; Heyman, HR; Holms, JH; Marcotte, PA; Michaelides, MR; Morgan, DW; Stacey, JR; Steinman, DH; Tapang, P; Wada, CK, 2002
)
0.31

Dosage Studied

Thirty-five patients with OA were randomized to receive oral daily dosing of BAY 12-9566 (25, 100, or 400 mg) or placebo for 3 weeks prior to knee surgery. There were no consistent effects on the plasma concentrations of MMP-2 and M MP-9 over the continuous dosing period at any dose level.

ExcerptRelevanceReference
"To evaluate the feasibility of administering BAY 12-9566, a matrix metalloproteinase (MMP) inhibitor with relative specificity against MMP-2, MMP-3, and MMP-9, on a protracted oral daily dosing schedule in patients with advanced solid malignancies."( Phase I and pharmacologic study of the specific matrix metalloproteinase inhibitor BAY 12-9566 on a protracted oral daily dosing schedule in patients with solid malignancies.
Aylesworth, C; Eckhardt, SG; Garner, A; Hammond, LA; Hidalgo, M; Humphrey, R; Morrow, M; Rowinsky, EK; Smetzer, L; Smith, L; Sorensen, JM; Von Hoff, DD, 2000
)
0.79
" There were no consistent effects of BAY 12-9566 on the plasma concentrations of MMP-2 and MMP-9 over the continuous dosing period at any dose schedule level."( Phase I and pharmacologic study of the specific matrix metalloproteinase inhibitor BAY 12-9566 on a protracted oral daily dosing schedule in patients with solid malignancies.
Aylesworth, C; Eckhardt, SG; Garner, A; Hammond, LA; Hidalgo, M; Humphrey, R; Morrow, M; Rowinsky, EK; Smetzer, L; Smith, L; Sorensen, JM; Von Hoff, DD, 2000
)
0.8
" as this dose provides maximal plasma levels that can be achieved with a convenient dosing schedule for a chronically administered oral agent."( A phase I dose escalation study of the matrix metalloproteinase inhibitor BAY 12-9566 administered orally in patients with advanced solid tumours.
Arnold, A; Bates, S; Bennett, K; Elias, I; Goel, R; Hirte, H; Holohan, S; Huan, S; Major, P; Seymour, L; Stewart, D; Walsh, W; Waterfield, B; Yau, J, 2000
)
0.54
" Patients with advanced solid tumours were enrolled in our study and plasma was collected on day 1 before dosing and at steady-state of the drug on day 15."( Quantification of matrix metalloproteinase activity in plasma of patients enrolled in a BAY 12-9566 phase I study.
Duivenvoorden, WC; Hirte, HW; Singh, G, 2001
)
0.53
"Thirty-five patients with OA were randomized to receive oral daily dosing of BAY 12-9566 (25, 100, or 400 mg) or placebo for 3 weeks prior to knee surgery."( Molecular changes in human osteoarthritic cartilage after 3 weeks of oral administration of BAY 12-9566, a matrix metalloproteinase inhibitor.
Elias, I; Ionescu, M; Leff, RL; Poole, AR; Reiner, A, 2003
)
0.77
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
organochlorine compoundAn organochlorine compound is a compound containing at least one carbon-chlorine bond.
biphenylsBenzenoid aromatic compounds containing two phenyl or substituted-phenyl groups which are joined together by a single bond.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (5)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Interstitial collagenaseHomo sapiens (human)IC50 (µMol)5.00000.00020.850210.0000AID109078
Interstitial collagenaseHomo sapiens (human)Ki5.00000.00030.49487.0000AID108922
72 kDa type IV collagenaseHomo sapiens (human)IC50 (µMol)0.01100.00001.284810.0000AID107333
72 kDa type IV collagenaseHomo sapiens (human)Ki0.01100.00000.34663.0000AID107316
Stromelysin-1Homo sapiens (human)IC50 (µMol)0.13400.00001.148410.0000AID107675
Stromelysin-1Homo sapiens (human)Ki0.14300.00030.54258.0000AID107532
Matrix metalloproteinase-9Homo sapiens (human)IC50 (µMol)0.30100.00000.705310.0000AID108303
Matrix metalloproteinase-9Homo sapiens (human)Ki0.30100.00020.12810.8000AID108171
Collagenase 3Homo sapiens (human)Ki1.47000.00000.47593.8000AID109390
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (74)

Processvia Protein(s)Taxonomy
proteolysisInterstitial collagenaseHomo sapiens (human)
protein metabolic processInterstitial collagenaseHomo sapiens (human)
extracellular matrix disassemblyInterstitial collagenaseHomo sapiens (human)
collagen catabolic processInterstitial collagenaseHomo sapiens (human)
positive regulation of protein-containing complex assemblyInterstitial collagenaseHomo sapiens (human)
cellular response to UV-AInterstitial collagenaseHomo sapiens (human)
extracellular matrix organizationInterstitial collagenaseHomo sapiens (human)
angiogenesis72 kDa type IV collagenaseHomo sapiens (human)
ovarian follicle development72 kDa type IV collagenaseHomo sapiens (human)
ovulation from ovarian follicle72 kDa type IV collagenaseHomo sapiens (human)
luteinization72 kDa type IV collagenaseHomo sapiens (human)
blood vessel maturation72 kDa type IV collagenaseHomo sapiens (human)
intramembranous ossification72 kDa type IV collagenaseHomo sapiens (human)
proteolysis72 kDa type IV collagenaseHomo sapiens (human)
negative regulation of cell adhesion72 kDa type IV collagenaseHomo sapiens (human)
heart development72 kDa type IV collagenaseHomo sapiens (human)
embryo implantation72 kDa type IV collagenaseHomo sapiens (human)
parturition72 kDa type IV collagenaseHomo sapiens (human)
response to xenobiotic stimulus72 kDa type IV collagenaseHomo sapiens (human)
response to mechanical stimulus72 kDa type IV collagenaseHomo sapiens (human)
peripheral nervous system axon regeneration72 kDa type IV collagenaseHomo sapiens (human)
response to activity72 kDa type IV collagenaseHomo sapiens (human)
protein metabolic process72 kDa type IV collagenaseHomo sapiens (human)
extracellular matrix disassembly72 kDa type IV collagenaseHomo sapiens (human)
protein catabolic process72 kDa type IV collagenaseHomo sapiens (human)
positive regulation of cell migration72 kDa type IV collagenaseHomo sapiens (human)
collagen catabolic process72 kDa type IV collagenaseHomo sapiens (human)
response to retinoic acid72 kDa type IV collagenaseHomo sapiens (human)
cellular response to reactive oxygen species72 kDa type IV collagenaseHomo sapiens (human)
response to nicotine72 kDa type IV collagenaseHomo sapiens (human)
endodermal cell differentiation72 kDa type IV collagenaseHomo sapiens (human)
response to hydrogen peroxide72 kDa type IV collagenaseHomo sapiens (human)
response to estrogen72 kDa type IV collagenaseHomo sapiens (human)
negative regulation of vasoconstriction72 kDa type IV collagenaseHomo sapiens (human)
ephrin receptor signaling pathway72 kDa type IV collagenaseHomo sapiens (human)
macrophage chemotaxis72 kDa type IV collagenaseHomo sapiens (human)
response to electrical stimulus72 kDa type IV collagenaseHomo sapiens (human)
response to hyperoxia72 kDa type IV collagenaseHomo sapiens (human)
face morphogenesis72 kDa type IV collagenaseHomo sapiens (human)
bone trabecula formation72 kDa type IV collagenaseHomo sapiens (human)
prostate gland epithelium morphogenesis72 kDa type IV collagenaseHomo sapiens (human)
cellular response to amino acid stimulus72 kDa type IV collagenaseHomo sapiens (human)
cellular response to interleukin-172 kDa type IV collagenaseHomo sapiens (human)
cellular response to estradiol stimulus72 kDa type IV collagenaseHomo sapiens (human)
cellular response to UV-A72 kDa type IV collagenaseHomo sapiens (human)
cellular response to fluid shear stress72 kDa type IV collagenaseHomo sapiens (human)
positive regulation of oxidative stress-induced neuron intrinsic apoptotic signaling pathway72 kDa type IV collagenaseHomo sapiens (human)
response to amyloid-beta72 kDa type IV collagenaseHomo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferation72 kDa type IV collagenaseHomo sapiens (human)
extracellular matrix organization72 kDa type IV collagenaseHomo sapiens (human)
response to hypoxia72 kDa type IV collagenaseHomo sapiens (human)
tissue remodeling72 kDa type IV collagenaseHomo sapiens (human)
proteolysisStromelysin-1Homo sapiens (human)
extracellular matrix disassemblyStromelysin-1Homo sapiens (human)
protein catabolic processStromelysin-1Homo sapiens (human)
regulation of cell migrationStromelysin-1Homo sapiens (human)
collagen catabolic processStromelysin-1Homo sapiens (human)
positive regulation of protein-containing complex assemblyStromelysin-1Homo sapiens (human)
cellular response to reactive oxygen speciesStromelysin-1Homo sapiens (human)
innate immune responseStromelysin-1Homo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionStromelysin-1Homo sapiens (human)
cellular response to lipopolysaccharideStromelysin-1Homo sapiens (human)
cellular response to amino acid stimulusStromelysin-1Homo sapiens (human)
cellular response to UV-AStromelysin-1Homo sapiens (human)
cellular response to nitric oxideStromelysin-1Homo sapiens (human)
regulation of neuroinflammatory responseStromelysin-1Homo sapiens (human)
response to amyloid-betaStromelysin-1Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processStromelysin-1Homo sapiens (human)
extracellular matrix organizationStromelysin-1Homo sapiens (human)
skeletal system developmentMatrix metalloproteinase-9Homo sapiens (human)
positive regulation of protein phosphorylationMatrix metalloproteinase-9Homo sapiens (human)
proteolysisMatrix metalloproteinase-9Homo sapiens (human)
apoptotic processMatrix metalloproteinase-9Homo sapiens (human)
embryo implantationMatrix metalloproteinase-9Homo sapiens (human)
cell migrationMatrix metalloproteinase-9Homo sapiens (human)
extracellular matrix disassemblyMatrix metalloproteinase-9Homo sapiens (human)
macrophage differentiationMatrix metalloproteinase-9Homo sapiens (human)
collagen catabolic processMatrix metalloproteinase-9Homo sapiens (human)
cellular response to reactive oxygen speciesMatrix metalloproteinase-9Homo sapiens (human)
endodermal cell differentiationMatrix metalloproteinase-9Homo sapiens (human)
positive regulation of apoptotic processMatrix metalloproteinase-9Homo sapiens (human)
negative regulation of apoptotic processMatrix metalloproteinase-9Homo sapiens (human)
positive regulation of DNA bindingMatrix metalloproteinase-9Homo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathwayMatrix metalloproteinase-9Homo sapiens (human)
ephrin receptor signaling pathwayMatrix metalloproteinase-9Homo sapiens (human)
positive regulation of keratinocyte migrationMatrix metalloproteinase-9Homo sapiens (human)
cellular response to lipopolysaccharideMatrix metalloproteinase-9Homo sapiens (human)
cellular response to cadmium ionMatrix metalloproteinase-9Homo sapiens (human)
cellular response to UV-AMatrix metalloproteinase-9Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaMatrix metalloproteinase-9Homo sapiens (human)
regulation of neuroinflammatory responseMatrix metalloproteinase-9Homo sapiens (human)
positive regulation of receptor bindingMatrix metalloproteinase-9Homo sapiens (human)
response to amyloid-betaMatrix metalloproteinase-9Homo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferationMatrix metalloproteinase-9Homo sapiens (human)
negative regulation of epithelial cell differentiation involved in kidney developmentMatrix metalloproteinase-9Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathwayMatrix metalloproteinase-9Homo sapiens (human)
negative regulation of cation channel activityMatrix metalloproteinase-9Homo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic signaling pathwayMatrix metalloproteinase-9Homo sapiens (human)
extracellular matrix organizationMatrix metalloproteinase-9Homo sapiens (human)
endochondral ossificationCollagenase 3Homo sapiens (human)
growth plate cartilage developmentCollagenase 3Homo sapiens (human)
proteolysisCollagenase 3Homo sapiens (human)
extracellular matrix disassemblyCollagenase 3Homo sapiens (human)
bone mineralizationCollagenase 3Homo sapiens (human)
collagen catabolic processCollagenase 3Homo sapiens (human)
bone morphogenesisCollagenase 3Homo sapiens (human)
response to amyloid-betaCollagenase 3Homo sapiens (human)
extracellular matrix organizationCollagenase 3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (11)

Processvia Protein(s)Taxonomy
endopeptidase activityInterstitial collagenaseHomo sapiens (human)
metalloendopeptidase activityInterstitial collagenaseHomo sapiens (human)
serine-type endopeptidase activityInterstitial collagenaseHomo sapiens (human)
peptidase activityInterstitial collagenaseHomo sapiens (human)
zinc ion bindingInterstitial collagenaseHomo sapiens (human)
fibronectin binding72 kDa type IV collagenaseHomo sapiens (human)
endopeptidase activity72 kDa type IV collagenaseHomo sapiens (human)
metalloendopeptidase activity72 kDa type IV collagenaseHomo sapiens (human)
serine-type endopeptidase activity72 kDa type IV collagenaseHomo sapiens (human)
protein binding72 kDa type IV collagenaseHomo sapiens (human)
metallopeptidase activity72 kDa type IV collagenaseHomo sapiens (human)
zinc ion binding72 kDa type IV collagenaseHomo sapiens (human)
endopeptidase activityStromelysin-1Homo sapiens (human)
metalloendopeptidase activityStromelysin-1Homo sapiens (human)
serine-type endopeptidase activityStromelysin-1Homo sapiens (human)
protein bindingStromelysin-1Homo sapiens (human)
peptidase activityStromelysin-1Homo sapiens (human)
metallopeptidase activityStromelysin-1Homo sapiens (human)
zinc ion bindingStromelysin-1Homo sapiens (human)
endopeptidase activityMatrix metalloproteinase-9Homo sapiens (human)
metalloendopeptidase activityMatrix metalloproteinase-9Homo sapiens (human)
serine-type endopeptidase activityMatrix metalloproteinase-9Homo sapiens (human)
protein bindingMatrix metalloproteinase-9Homo sapiens (human)
collagen bindingMatrix metalloproteinase-9Homo sapiens (human)
peptidase activityMatrix metalloproteinase-9Homo sapiens (human)
metallopeptidase activityMatrix metalloproteinase-9Homo sapiens (human)
zinc ion bindingMatrix metalloproteinase-9Homo sapiens (human)
identical protein bindingMatrix metalloproteinase-9Homo sapiens (human)
endopeptidase activityCollagenase 3Homo sapiens (human)
metalloendopeptidase activityCollagenase 3Homo sapiens (human)
serine-type endopeptidase activityCollagenase 3Homo sapiens (human)
calcium ion bindingCollagenase 3Homo sapiens (human)
collagen bindingCollagenase 3Homo sapiens (human)
zinc ion bindingCollagenase 3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (12)

Processvia Protein(s)Taxonomy
extracellular regionInterstitial collagenaseHomo sapiens (human)
extracellular matrixInterstitial collagenaseHomo sapiens (human)
extracellular spaceInterstitial collagenaseHomo sapiens (human)
collagen-containing extracellular matrix72 kDa type IV collagenaseHomo sapiens (human)
extracellular region72 kDa type IV collagenaseHomo sapiens (human)
extracellular space72 kDa type IV collagenaseHomo sapiens (human)
nucleus72 kDa type IV collagenaseHomo sapiens (human)
mitochondrion72 kDa type IV collagenaseHomo sapiens (human)
plasma membrane72 kDa type IV collagenaseHomo sapiens (human)
sarcomere72 kDa type IV collagenaseHomo sapiens (human)
collagen-containing extracellular matrix72 kDa type IV collagenaseHomo sapiens (human)
extracellular space72 kDa type IV collagenaseHomo sapiens (human)
extracellular regionStromelysin-1Homo sapiens (human)
nucleusStromelysin-1Homo sapiens (human)
mitochondrionStromelysin-1Homo sapiens (human)
cytosolStromelysin-1Homo sapiens (human)
extracellular matrixStromelysin-1Homo sapiens (human)
extracellular spaceStromelysin-1Homo sapiens (human)
extracellular regionMatrix metalloproteinase-9Homo sapiens (human)
extracellular spaceMatrix metalloproteinase-9Homo sapiens (human)
collagen-containing extracellular matrixMatrix metalloproteinase-9Homo sapiens (human)
extracellular exosomeMatrix metalloproteinase-9Homo sapiens (human)
tertiary granule lumenMatrix metalloproteinase-9Homo sapiens (human)
ficolin-1-rich granule lumenMatrix metalloproteinase-9Homo sapiens (human)
extracellular spaceMatrix metalloproteinase-9Homo sapiens (human)
extracellular regionCollagenase 3Homo sapiens (human)
extracellular matrixCollagenase 3Homo sapiens (human)
extracellular spaceCollagenase 3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (10)

Assay IDTitleYearJournalArticle
AID108922Inhibition of matrix metalloprotease-1 (MMP-1).2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
Protease inhibitors: current status and future prospects.
AID107316Inhibition of matrix metalloprotease-2 (MMP-2).2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
Protease inhibitors: current status and future prospects.
AID109078In vitro selective inhibition against matrix metalloprotease-1 (MMP-1) using a fluorimetric assay2002Journal of medicinal chemistry, Jan-03, Volume: 45, Issue:1
Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.
AID108171Inhibition of matrix metalloprotease-9 (MMP-9).2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
Protease inhibitors: current status and future prospects.
AID107675Inhibition of Matrix metalloprotease-3 (MMP-3) in fluorimetric assay2002Journal of medicinal chemistry, Jan-03, Volume: 45, Issue:1
Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.
AID108303In vitro selective inhibition against Matrix metalloprotease-9 (MMP-9) using fluorimetric assay2002Journal of medicinal chemistry, Jan-03, Volume: 45, Issue:1
Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.
AID107333In vitro selective inhibition against matrix metalloprotease-2 (MMP-2) using fluorimetric assay2002Journal of medicinal chemistry, Jan-03, Volume: 45, Issue:1
Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.
AID109390Inhibition of matrix metalloprotease-13 (MMP-13).2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
Protease inhibitors: current status and future prospects.
AID107532Inhibition of matrix metalloprotease-3 (MMP-3).2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
Protease inhibitors: current status and future prospects.
AID1345417Human MMP2 (M10: Matrix metallopeptidase)2006Cancer metastasis reviews, Mar, Volume: 25, Issue:1
Recent advances in MMP inhibitor design.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (47)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's8 (17.02)18.2507
2000's36 (76.60)29.6817
2010's2 (4.26)24.3611
2020's1 (2.13)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.47

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.47 (24.57)
Research Supply Index4.16 (2.92)
Research Growth Index4.63 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.47)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials15 (31.25%)5.53%
Reviews10 (20.83%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other23 (47.92%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]